Dr. Furberg is a molecular epidemiologist conducting research to identify factors associated with genitourinary cancer etiology and prognosis, and genetic factors associated with smoking behavior and response to chemotherapy. She is Co-PI of the MSK Urothelial Cancer Registry, an institutional resource to identify genetic and non-genetic factors associated with bladder cancer risk and outcomes. She was recently funded by the American Cancer Society to establish a prospective study to determine the impact of post-diagnosis smoking on bladder cancer recurrence risk and BCG treatment. She also received a V Foundation Cancer Research grant to identify germline variants associated with response to platinum-based chemotherapy in bladder cancer patients. Together with colleagues at MSK and at Weill Cornell, she also investigates how body size impacts kidney cancer mortality, and how risk factors for kidney cancer are associated with tumor characteristics.
Media CoverageObesity Increases Men's Risk of Dying from Prostate Cancer
Media CoverageSmoking Gene May Reveal Why Some People Smoke More